Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

2026-07-14 07:00:00

Phase 1 Study Designed to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-587 in Healthy Volunteers AT-587 is a Potential First-in Class Treatment for Hepatitis E Virus, a Serious Liver Disease with No Approved Therapies Study Initiation Represents an Important Milestone Advancing Atea's Antiviral Pipeline Focusing on First- or Best-in-Class Product Candidates in Areas of High Unmet Medical Need BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the initiation of a first-in-human Phase 1 clinical trial evaluating AT-587, for the treatment of hepatitis E virus (HEV) infection. AT-587 is a proprietary oral antiviral nucleotide analog being developed for the treatment of HEV, a potentially serious liver disease that can lead to chronic infection, cirrhosis and liver failure in certain patient populations.

Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

2026-06-25 07:00:00

Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North America C-FORWARD and C-BEYOND Represent the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for the Treatment of HCV BOSTON, June 25, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced completion of patient enrollment in C-FORWARD, its Phase 3 clinical trial outside North America, evaluating the regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) infection. The anticipated topline results from C-BEYOND, the Phase 3 trial conducted in the US and Canada, remain on track for mid-year 2026.

Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know

2026-06-18 13:00:40

Atea Pharmaceuticals (AVIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?

2026-06-09 10:41:19

Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed compared to their sector so far this year.

Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst

2026-05-29 11:19:52

Atea Pharmaceuticals, Inc. receives a buy rating ahead of pivotal phase 3 BEM/RZR hepatitis C data expected mid-2026. AVIR's BEM/RZR targets a differentiated, short-duration, pan-genotypic HCV regimen, aiming for >95% sustained virologic response and low drug-drug interactions. AVIR's $256m cash runway extends through 2027, but commercial viability hinges on phase 3 success versus entrenched competitors Gilead and AbbVie.

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

2026-05-27 07:00:00

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. These results support the use of BEM/RZR with commonly used medications, including the proton pump inhibitor (PPI) omeprazole and the cholesterol-lowering drug rosuvastatin.

Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround

2026-05-15 10:37:17

Atea Pharmaceuticals (AVIR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline

2026-05-13 07:00:00

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27-30th in Barcelona, Spain.